• The Outperformers (91-100)

  These companies have been ranked based on their stock's excess return over the Sensex for a five-year period

  September 10, 2019

• New growth model

  Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?

  Kripa Mahalingam - July 26, 2019

• Opportunistic Buyer

  Sailesh Raj Bhan has made optimum use of cyclical downturns to deliver outperformance

  Khushboo Balani - January 25, 2018

• Is the worst over for pharma stocks?

  The pharma index has hugely underperformed the Sensex in CY17 owing to regulatory overhang and FDA issues 

  July 17, 2017

• Oh No! Aurobindo

  The recent negative news flow has led to a selling spree in Aurobindo Pharma

  Jash Kriplani - January 24, 2017

• Good Timing

  Aurobindo Pharma promoters sell over 10 million shares in a market transaction valued at Rs.900 crore

  Jitendra Kumar Gupta - October 14, 2016

• Self-healing

  Hyderabad’s pharma players are adapting to a regulatory backlash and fighting back against dumping from China

  Krishna Gopalan - March 09, 2016

• Overdosing on growth

  A shift in focus in the US and the EU has propelled the stock price of Aurobindo Pharma to an all-time high

  Adit Mathai - April 20, 2015